Publicação

In vitro transcribed mRNA optimization for gene therapy in the eye

Ver documento

Detalhes bibliográficos
Resumo:Inherited retinal diseases (IRDs) represent a heterogeneous group of degenerative diseases, caused by around 300 gene mutations, without an effective treatment. IRDs constitute the leading cause of blindness worldwide, with a prevalence of 1 in 2000 individuals. Gene therapy emerges as a promis- ing therapeutic option for the possible treatment of IRDs. Recent advancements in mRNA therapeutics motivated the exploration of in vitro transcribed mRNA for therapeutic applications including the COVID- 19 vaccines. Despite the success of mRNA-based vaccination, little research has been done on the application of mRNA technology for ocular diseases. Delivering mRNA to the retina holds substantial advantages, as mRNA is completely functional in the cytoplasm and does not require nuclear entry, hence does not integrate with the genome. Furthermore, it presents a transient nature, low-cost produc- tion, and low immunogenicity. This project aims to explore mRNA efficiency in two retinal pigment epi- thelium (RPE) cell models: ARPE-19, human induced Pluripotent Stem Cells-derived RPE (hiPSCs- RPE) and also retinal organoids. In this work, the delivery of a mRNA (GFPmRNA) using commercial lipid-based nanoparticles (LNPs) was explored. Results demonstrated that mRNA is efficiently delivered to RPE in a short time (1h-3h). Moreover, mRNA complexed with LNPs, successfully transfect both ARPE-19 and hiPSCs- RPE, that lasted up to 30 days without toxicity. Notably, complexed mRNA demonstrated superior transfection efficiency compared to pDNA and AAV2 strategies. On the other hand, AAV6 exhibited similar efficiency compared to mRNA delivery in hiPSCs-RPE and higher in ARPE-19. Despite this, the increased expression of MCP1 was only observed in viral delivery compared to mRNA transfection, suggesting potential immunogenicity. Furthermore, in retinal organoids only few Müller glia cells were transfected. In summary, this study showed a clear advantage of mRNA delivery compared to other strate- gies in RPE cells and highlights the potential for developing mRNA-based gene therapies for the treatment of IRDs.
Autores principais:Castro, Mariana Parreiras Dias Urbano de
Assunto:lARPE-19 Gene therapy human induced Pluripotent Stem Cells mRNA Lipid Nanoparticles Retinal Organoids
Ano:2023
País:Portugal
Tipo de documento:dissertação de mestrado
Tipo de acesso:acesso embargado
Instituição associada:Universidade Nova de Lisboa
Idioma:inglês
Origem:Repositório Institucional da UNL
_version_ 1868983221808529408
author Castro, Mariana Parreiras Dias Urbano de
author_facet Castro, Mariana Parreiras Dias Urbano de
author_role author
contributor_name_str_mv Lemos, Luisa
Braga, Margarida
RUN
country_str PT
creators_json_txt [{\"Person.name\":\"Castro, Mariana Parreiras Dias Urbano de\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Lemos, Luisa
Braga, Margarida
RUN
datacite.creators.creator.creatorName.fl_str_mv Castro, Mariana Parreiras Dias Urbano de
datacite.date.Accepted.fl_str_mv 2023-11-28T00:00:00Z
datacite.date.available.fl_str_mv 2026-09-30T00:00:00Z
datacite.date.embargoed.fl_str_mv 2026-09-30T00:00:00Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_f1cf
datacite.subjects.subject.fl_str_mv lARPE-19
Gene therapy
human induced Pluripotent Stem Cells
mRNA
Lipid Nanoparticles
Retinal Organoids
datacite.titles.title.fl_str_mv In vitro transcribed mRNA optimization for gene therapy in the eye
dc.contributor.none.fl_str_mv Lemos, Luisa
Braga, Margarida
RUN
dc.creator.none.fl_str_mv Castro, Mariana Parreiras Dias Urbano de
dc.date.Accepted.fl_str_mv 2023-11-28T00:00:00Z
dc.date.available.fl_str_mv 2026-09-30T00:00:00Z
dc.date.embargoed.fl_str_mv 2026-09-30T00:00:00Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv http://hdl.handle.net/10362/161846
dc.language.none.fl_str_mv eng
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_f1cf
dc.subject.none.fl_str_mv lARPE-19
Gene therapy
human induced Pluripotent Stem Cells
mRNA
Lipid Nanoparticles
Retinal Organoids
dc.title.fl_str_mv In vitro transcribed mRNA optimization for gene therapy in the eye
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_bdcc
description Inherited retinal diseases (IRDs) represent a heterogeneous group of degenerative diseases, caused by around 300 gene mutations, without an effective treatment. IRDs constitute the leading cause of blindness worldwide, with a prevalence of 1 in 2000 individuals. Gene therapy emerges as a promis- ing therapeutic option for the possible treatment of IRDs. Recent advancements in mRNA therapeutics motivated the exploration of in vitro transcribed mRNA for therapeutic applications including the COVID- 19 vaccines. Despite the success of mRNA-based vaccination, little research has been done on the application of mRNA technology for ocular diseases. Delivering mRNA to the retina holds substantial advantages, as mRNA is completely functional in the cytoplasm and does not require nuclear entry, hence does not integrate with the genome. Furthermore, it presents a transient nature, low-cost produc- tion, and low immunogenicity. This project aims to explore mRNA efficiency in two retinal pigment epi- thelium (RPE) cell models: ARPE-19, human induced Pluripotent Stem Cells-derived RPE (hiPSCs- RPE) and also retinal organoids. In this work, the delivery of a mRNA (GFPmRNA) using commercial lipid-based nanoparticles (LNPs) was explored. Results demonstrated that mRNA is efficiently delivered to RPE in a short time (1h-3h). Moreover, mRNA complexed with LNPs, successfully transfect both ARPE-19 and hiPSCs- RPE, that lasted up to 30 days without toxicity. Notably, complexed mRNA demonstrated superior transfection efficiency compared to pDNA and AAV2 strategies. On the other hand, AAV6 exhibited similar efficiency compared to mRNA delivery in hiPSCs-RPE and higher in ARPE-19. Despite this, the increased expression of MCP1 was only observed in viral delivery compared to mRNA transfection, suggesting potential immunogenicity. Furthermore, in retinal organoids only few Müller glia cells were transfected. In summary, this study showed a clear advantage of mRNA delivery compared to other strate- gies in RPE cells and highlights the potential for developing mRNA-based gene therapies for the treatment of IRDs.
dirty 0
eu_rights_str_mv embargoedAccess
format masterThesis
fulltext.url.fl_str_mv https://run.unl.pt/bitstreams/c8cfc440-48cb-411c-8ea3-c608ec910d3f/download
id run_c5372efcd561decaec68deedfad09fbb
identifier.url.fl_str_mv http://hdl.handle.net/10362/161846
inst_facet_str urn:organizationAcronym:unl{{{_:::_}}}Universidade Nova de Lisboa
instacron_str unl
institution Universidade Nova de Lisboa
instname_str Universidade Nova de Lisboa
language eng
network_acronym_str run
network_name_str Repositório Institucional da UNL
oai_identifier_str oai:run.unl.pt:10362/161846
organization_str_mv urn:organizationAcronym:unl
person_str_mv Castro, Mariana Parreiras Dias Urbano de
publishDate 2023
repo_facet_str urn:repositoryAcronym:run{{{_:::_}}}Repositório Institucional da UNL
reponame_str Repositório Institucional da UNL
repository_id_str urn:repositoryAcronym:run
service_str_mv urn:repositoryAcronym:run
spelling engpt_PTInherited retinal diseases (IRDs) represent a heterogeneous group of degenerative diseases, caused by around 300 gene mutations, without an effective treatment. IRDs constitute the leading cause of blindness worldwide, with a prevalence of 1 in 2000 individuals. Gene therapy emerges as a promis- ing therapeutic option for the possible treatment of IRDs. Recent advancements in mRNA therapeutics motivated the exploration of in vitro transcribed mRNA for therapeutic applications including the COVID- 19 vaccines. Despite the success of mRNA-based vaccination, little research has been done on the application of mRNA technology for ocular diseases. Delivering mRNA to the retina holds substantial advantages, as mRNA is completely functional in the cytoplasm and does not require nuclear entry, hence does not integrate with the genome. Furthermore, it presents a transient nature, low-cost produc- tion, and low immunogenicity. This project aims to explore mRNA efficiency in two retinal pigment epi- thelium (RPE) cell models: ARPE-19, human induced Pluripotent Stem Cells-derived RPE (hiPSCs- RPE) and also retinal organoids. In this work, the delivery of a mRNA (GFPmRNA) using commercial lipid-based nanoparticles (LNPs) was explored. Results demonstrated that mRNA is efficiently delivered to RPE in a short time (1h-3h). Moreover, mRNA complexed with LNPs, successfully transfect both ARPE-19 and hiPSCs- RPE, that lasted up to 30 days without toxicity. Notably, complexed mRNA demonstrated superior transfection efficiency compared to pDNA and AAV2 strategies. On the other hand, AAV6 exhibited similar efficiency compared to mRNA delivery in hiPSCs-RPE and higher in ARPE-19. Despite this, the increased expression of MCP1 was only observed in viral delivery compared to mRNA transfection, suggesting potential immunogenicity. Furthermore, in retinal organoids only few Müller glia cells were transfected. In summary, this study showed a clear advantage of mRNA delivery compared to other strate- gies in RPE cells and highlights the potential for developing mRNA-based gene therapies for the treatment of IRDs.application/pdfpt_PTIn vitro transcribed mRNA optimization for gene therapy in the eyeCastro, Mariana Parreiras Dias Urbano deLemos, LuisaBraga, MargaridaHostingInstitutionOrganizationalRUNe-mailmailto:run@unl.ptrun@unl.pt2023-11-282026-09-30T00:00:00Z2023-11-28T00:00:00ZHandlehttp://hdl.handle.net/10362/161846http://purl.org/coar/access_right/c_f1cfembargoed accesslARPE-19Gene therapyhuman induced Pluripotent Stem CellsmRNALipid NanoparticlesRetinal Organoids44587575 bytesliteraturehttp://purl.org/coar/resource_type/c_bdccmaster thesishttp://purl.org/coar/access_right/c_f1cfapplication/pdffulltexthttps://run.unl.pt/bitstreams/c8cfc440-48cb-411c-8ea3-c608ec910d3f/download
spellingShingle In vitro transcribed mRNA optimization for gene therapy in the eye
Castro, Mariana Parreiras Dias Urbano de
lARPE-19
Gene therapy
human induced Pluripotent Stem Cells
mRNA
Lipid Nanoparticles
Retinal Organoids
status SINGLETON
subject.fl_str_mv lARPE-19
Gene therapy
human induced Pluripotent Stem Cells
mRNA
Lipid Nanoparticles
Retinal Organoids
title In vitro transcribed mRNA optimization for gene therapy in the eye
title_full In vitro transcribed mRNA optimization for gene therapy in the eye
title_fullStr In vitro transcribed mRNA optimization for gene therapy in the eye
title_full_unstemmed In vitro transcribed mRNA optimization for gene therapy in the eye
title_short In vitro transcribed mRNA optimization for gene therapy in the eye
title_sort In vitro transcribed mRNA optimization for gene therapy in the eye
topic lARPE-19
Gene therapy
human induced Pluripotent Stem Cells
mRNA
Lipid Nanoparticles
Retinal Organoids
topic_facet lARPE-19
Gene therapy
human induced Pluripotent Stem Cells
mRNA
Lipid Nanoparticles
Retinal Organoids
url http://hdl.handle.net/10362/161846
visible 1